Advertisement

Search Results for "Healthpoint Biotherapeutics Revenue"

20:34 EDT 18th June 2013 | BioPortfolio

Matching Channels

Biotherapeutics - news, views, reports and blogs

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Latest Biotherapeutics News - RSS feed - Twitter account - @Biotherapeutic1 -...

Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...

iBioLaunch

The iBioLaunch™ platform is a  proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins.  The plants are easily and...

BioPortfolio Twitter Accounts

BioPortfolio has created a number of Twitter accounts to help you keep upto date on the latest news, research papers, reports and clinical trials on a selected range of important and popular topics....

Matching News

Smith & Nephew acquires Healthpoint Biotherapeutics for $782 million

Smith & Nephew has signed an agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash. Healthpoint Biotherapeutics has been focused on biopharma...

Healthpoint Biotherapeutics announces HP802-247 clinical trial results

Biopharmaceutical company Healthpoint Biotherapeutics has announced the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers, which is published in jour...

Healthpoint Buy To Double Smith & Nephew's U.S. Wound Operations

By EP Vantage:Smith & Nephew (SNN) has long been spoken of as a takeover target, but instead it has itself pounced on Healthpoint Biotherapeutics, a specialist in bioactive woundcare – the fas...

News Summary: Smith & Nephew buys Healthpoint

THE DEAL: British medical technology company Smith & Nephew PLC is buying Texas-based Healthpoint Biotherapeutics for $782 million.THE TARGET: Healthpoint Biotherapeutics, founded in 1992, is a privat...

Smith & Nephew Buys Healthpoint Biotherapeutics

Smith Nephew has acquired Healthpoint Biotherapeutics for USD 782 million in cash, in a move designed...

Smith & Nephew to acquire DFB dermatology subsidiary

Smith & Nephew plc (LSE:SN; NYSE:SNN) will acquire the Healthpoint Biotherapeutics subsidiary of DFB Pharmaceuticals Inc. (Fort Worth, Texas) for $782 million in cash. Smith & Nephew, which plans to i...

Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics

FORT WORTH, Texas, Nov. 28, 2012 /- Smith & Nephew (LSE: SN, NYSE: SNN ), the global medical technology business, announced today that it has signed an agreement to acquire substantially al...

Smith & Nephew to Acquire Assets Of Healthpoint Biotherapeutics

Smith & Nephew has signed an agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash.

Matching PubMed Articles

Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions.

Biotherapeutics, including recombinant or plasma-derived human proteins and antibody-based molecules, have emerged as an important class of pharmaceuticals. Aggregation and immunogenicity are among th...

Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration.

The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics. Key products on the biotherapeutic market such as insulins, but also several immunoglobulins or Fc-fusion...

Subcutaneous administration of biotherapeutics: Current experience in animal models.

In recent years, many peptide- and protein-based biotherapeutics have been approved for subcutaneous (SC) delivery. The mechanisms and factors affecting the uptake and distribution of such large molec...

Protein Particulate Detection Issues in Biotherapeutics Development-Current Status.

Formation of aggregates and particulates in biopharmaceutical formulation continues to be one of the major quality concerns in biotherapeutics development. The presence of large quantities of aggregat...

Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.

An immune response to a biotherapeutic can be induced when the therapeutic is processed and presented by antigen presenting cell to T helper cells. This study evaluates the performance of an in vitro...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement